The WHO has turned down Serum Institute of India’s proposal in search of extension of the shelf lifetime of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from 6 to 9 months, citing inadequate info, resources claimed.
The WHO has also sought a assembly with Medication Controller Typical of India (DCGI) to examine the make any difference, they claimed.
The transfer will come even as India’s drug regulator has extended Covishield’s shelf lifetime from 6 to 9 months from its production date.
In a latest communique to Pune-centered Serum Institute of India (SII), the WHO has also asked the agency to formulate the doses with ample titer and/or put into action a bigger specification at launch so that the least specification of= 2.5 x108ifu/dose is fulfilled all over the shelf lifetime.
Shelf lifetime is the size of time for which an merchandise remains match for use.
The DCGI in a letter to SII in